biostudies-literatureKim HPNIDDK NIH HHSNCRR NIH HHSNational Institute of Diabetes and Digestive and Kidney Diseases2199-2201https://www.ebi.ac.uk/biostudies/studies/S-EPMC8007645biostudies-literatureUnknown19(10)Oxaliplatin is an alkylating agent given with fluorouracil and leucovorin as a mainstay adjuvant chemotherapy for stage III colorectal cancer (CRC). Liver injury from oxaliplatin ranges from mild liver enzyme increases in 42% to 57% of patients in clinical trials¹ to rare severe injury leading to acute liver failure.² Chronic injury from endothelial cell damage and architectural distortion may manifest years later with nodular regenerative hyperplasia (NRH), portal sclerosis, and noncirrhotic portal hypertension (NCPH).²^,³ Chronic subclinical injury occurs in up to 78% of patients.³ Diagnosis may be confounded by nonalcoholic fatty liver disease (NAFLD), and long-term outcomes from chronic injury are unclear.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological AssociationThe Clinical Spectrum and Diagnosis of Oxaliplatin Liver Injury in the Era of Nonalcoholic Fatty Liver Disease.PMC8007645U01 DK065201U01 DK065211U01 DK065176U01 DK083023U01 DK083020U01 DK083027U01 DK100928U01 DK082992U24 DK065176U01 DK065238UL1 RR025747UL1 RR024986U01 DK065184UL1 RR024134UL1 RR024982U01 DK065193UL1 RR025761T32 DK007634UL1 RR024150Hayashi PHOdin JNavarro VZacks SKleiner DEKim HPDrug-Induced Liver Injury Network InvestigatorsfalseThe Clinical Spectrum and Diagnosis of Oxaliplatin Liver Injury in the Era of Nonalcoholic Fatty Liver Disease.Oxaliplatin is an alkylating agent given with fluorouracil and leucovorin as a mainstay adjuvant chemotherapy for stage III colorectal cancer (CRC). Liver injury from oxaliplatin ranges from mild liver enzyme increases in 42% to 57% of patients in clinical trials¹ to rare severe injury leading to acute liver failure.² Chronic injury from endothelial cell damage and architectural distortion may manifest years later with nodular regenerative hyperplasia (NRH), portal sclerosis, and noncirrhotic portal hypertension (NCPH).²^,³ Chronic subclinical injury occurs in up to 78% of patients.³ Diagnosis may be confounded by nonalcoholic fatty liver disease (NAFLD), and long-term outcomes from chronic injury are unclear.2021-01-01T00:00:00Z2021 Oct2025-04-03T22:35:42.757Z2024-10-16T04:30:41.231ZS-EPMC80076453300750710.1016/j.cgh.2020.09.038